Literature DB >> 22892755

Progression of cutaneous melanoma: implications for treatment.

Stanley P L Leong1, Martin C Mihm, George F Murphy, Dave S B Hoon, Mohammed Kashani-Sabet, Sanjiv S Agarwala, Jonathan S Zager, Axel Hauschild, Vernon K Sondak, Valerie Guild, John M Kirkwood.   

Abstract

The survival rates of melanoma, like any type of cancer, become worse with advancing stage. Spectrum theory is most consistent with the progression of melanoma from the primary site to the in-transit locations, regional or sentinel lymph nodes and beyond to the distant sites. Therefore, early diagnosis and surgical treatment before its spread is the most effective treatment. Recently, new approaches have revolutionized the diagnosis and treatment of melanoma. Genomic profiling and sequencing will form the basis for molecular taxonomy for more accurate subgrouping of melanoma patients in the future. New insights of molecular mechanisms of metastasis are summarized in this review article. Sentinel lymph node biopsy has become a standard of care for staging primary melanoma without the need for a more morbid complete regional lymph node dissection. With recent developments in molecular biology and genomics, novel molecular targeted therapy is being developed through clinical trials.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22892755      PMCID: PMC4311146          DOI: 10.1007/s10585-012-9521-1

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  144 in total

1.  Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

Authors:  Stergios J Moschos; Howard D Edington; Stephanie R Land; Uma N Rao; Drazen Jukic; Janice Shipe-Spotloe; John M Kirkwood
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

2.  Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database.

Authors:  Richard L White; Gregory D Ayers; Virginia H Stell; Shouluan Ding; Jeffrey E Gershenwald; Jonathan C Salo; Barbara A Pockaj; Richard Essner; Mark Faries; Kim James Charney; Eli Avisar; Axel Hauschild; Friederike Egberts; Bruce J Averbook; Carlos A Garberoglio; John T Vetto; Merrick I Ross; David Chu; Vijay Trisal; Harald Hoekstra; Eric Whitman; Harold J Wanebo; Daniel Debonis; Michael Vezeridis; Aaron Chevinsky; Mohammed Kashani-Sabet; Yu Shyr; Lynne Berry; Zhiguo Zhao; Seng-Jaw Soong; Stanley P L Leong
Journal:  Ann Surg Oncol       Date:  2011-06-07       Impact factor: 5.344

Review 3.  Karnofsky Memorial Lecture. Natural history of small breast cancers.

Authors:  S Hellman
Journal:  J Clin Oncol       Date:  1994-10       Impact factor: 44.544

4.  A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma.

Authors:  H Starz; B R Balda; K U Krämer; H Büchels; H Wang
Journal:  Cancer       Date:  2001-06-01       Impact factor: 6.860

5.  Stromal expression of MMP-13 is required for melanoma invasion and metastasis.

Authors:  Paola Zigrino; Isolde Kuhn; Tobias Bäuerle; Jan Zamek; Jay W Fox; Susanne Neumann; Alexander Licht; Marina Schorpp-Kistner; Peter Angel; Cornelia Mauch
Journal:  J Invest Dermatol       Date:  2009-06-11       Impact factor: 8.551

Review 6.  Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

Authors:  Thomas K Eigentler; Ulrich M Caroli; Peter Radny; Claus Garbe
Journal:  Lancet Oncol       Date:  2003-12       Impact factor: 41.316

7.  Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.

Authors:  Helen Gogas; John M Kirkwood; Christine S Falk; Urania Dafni; Vernon K Sondak; Dimosthenis Tsoutsos; Alexandros Stratigos; Christos Markopoulos; Dimitrios Pectasides; Maria Spyropoulou-Vlachou
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

Review 8.  Molecular basis of metastasis.

Authors:  Anne C Chiang; Joan Massagué
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

9.  The role of selective lymphadenectomy in the management of patients with malignant melanoma.

Authors:  L F Glass; N A Fenske; J L Messina; C W Cruse; D P Rapaport; C Berman; C A Puleo; R Heller; G Miliotes; J Albertini
Journal:  Dermatol Surg       Date:  1995-11       Impact factor: 3.398

Review 10.  Sentinel lymph node mapping and selective lymphadenectomy: the standard of care for melanoma.

Authors:  Stanley P L Leong
Journal:  Curr Treat Options Oncol       Date:  2004-06
View more
  12 in total

1.  Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.

Authors:  David J Monsma; David M Cherba; Emily E Eugster; Dawna L Dylewski; Paula T Davidson; Chelsea A Peterson; Andrew S Borgman; Mary E Winn; Karl J Dykema; Craig P Webb; Jeffrey P MacKeigan; Nicholas S Duesbery; Brian J Nickoloff; Noel R Monks
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

Review 2.  Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.

Authors:  Dale Han; Daniel C Thomas; Jonathan S Zager; Barbara Pockaj; Richard L White; Stanley Pl Leong
Journal:  World J Clin Oncol       Date:  2016-04-10

3.  Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas.

Authors:  Minhyung Kim; Nickolay Neznanov; Chandler D Wilfong; Daria I Fleyshman; Andrei A Purmal; Gary Haderski; Patricia Stanhope-Baker; Catherine A Burkhart; Katerina V Gurova; Andrei V Gudkov; Joseph J Skitzki
Journal:  Cancer Res       Date:  2016-09-28       Impact factor: 12.701

4.  A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion.

Authors:  Joseph A Wawrzyniak; Anna Bianchi-Smiraglia; Wiam Bshara; Sudha Mannava; Jeff Ackroyd; Archis Bagati; Angela R Omilian; Michael Im; Natalia Fedtsova; Jeffrey C Miecznikowski; Kalyana C Moparthy; Shoshanna N Zucker; Qianqian Zhu; Nadezhda I Kozlova; Albert E Berman; Keith S Hoek; Andrei V Gudkov; Donna S Shewach; Carl D Morrison; Mikhail A Nikiforov
Journal:  Cell Rep       Date:  2013-10-17       Impact factor: 9.423

5.  Precision Diagnosis Of Melanoma And Other Skin Lesions From Digital Images.

Authors:  Abhishek Bhattacharya; Albert Young; Andrew Wong; Simone Stalling; Maria Wei; Dexter Hadley
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2017-07-26

Review 6.  Advances in Immunotherapy for Melanoma: A Comprehensive Review.

Authors:  Carmen Rodríguez-Cerdeira; Miguel Carnero Gregorio; Adriana López-Barcenas; Elena Sánchez-Blanco; Beatriz Sánchez-Blanco; Gabriella Fabbrocini; Brunilda Bardhi; Ardiana Sinani; Roberto Arenas Guzman
Journal:  Mediators Inflamm       Date:  2017-08-01       Impact factor: 4.711

7.  Low-diluted Phenacetinum disrupted the melanoma cancer cell migration.

Authors:  Camille Fuselier; Christine Terryn; Alexandre Berquand; Jean-Marc Crowet; Arnaud Bonnomet; Michael Molinari; Manuel Dauchez; Laurent Martiny; Christophe Schneider
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

8.  Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.

Authors:  Maria Colombino; Amelia Lissia; Mariaelena Capone; Vincenzo De Giorgi; Daniela Massi; Ignazio Stanganelli; Ester Fonsatti; Michele Maio; Gerardo Botti; Corrado Caracò; Nicola Mozzillo; Paolo A Ascierto; Antonio Cossu; Giuseppe Palmieri
Journal:  J Transl Med       Date:  2013-08-29       Impact factor: 5.531

9.  Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma.

Authors:  Jie Shi; Bingyu Guo; Yu Zhang; Qiang Hui; Peng Chang; Kai Tao
Journal:  Biologics       Date:  2016-07-05

10.  7-dehydrocholesterol suppresses melanoma cell proliferation and invasion via Akt1/NF-κB signaling.

Authors:  Jia Liu; Feiliang Zhong; Lei Cao; Ruiying Zhu; Junze Qu; Lin Yang; Tingting Chen; Yunlong Hu; Ying Wang; Mingdong Yao; Wenhai Xiao; Chun Li; Bo Li; Yingjin Yuan
Journal:  Oncol Lett       Date:  2020-10-29       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.